PDC 1421

Drug Profile

PDC 1421

Alternative Names: BLI-1005; PDC-1421

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medical and Pharmaceutical Industry Technology and Development Center
  • Developer BioLite Inc
  • Class Antidepressants; Traditional-Chinese-medicine
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 08 Sep 2017 Phase-II development is ongoing in USA and Taiwan (PO) (NCT02395978)
  • 15 Dec 2016 Biomarkers information updated
  • 08 Mar 2016 BioLite plans a phase II trial for Attention deficit hyperactivity disorder in USA (NCT02699086)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top